Abstract:Abstract Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of cutaneous T-cell lymphoma (CTCL). MF is primarily a benign disease often confined to skin. MF, in about 10% of cases, can progress to SS or transform to large-cell histology. SS, the leukemic variant of CTCL, is defined as erythroderma on ≥ 80% of the skin plus ≥1000/μL circulating malignant T-cells. SS is very aggressive with a median overall survival of only 2-5 years. So far, effective treatment options for CTCLs are still very limited and the underlying genetic basis remains incompletely characterized. Here, we performed integrated genomic analyses of 105 patients with de novo or transformed SS, using whole-exome, targeted exon, transcriptome sequencing and SNP array. Frequent somatic alterations were identified in TP53, CARD11, CCR4, PLCG1, TNFRSF1B, CDKN2A, ARID1A, RPS6KA1 and ZEB1. Activating CCR4 and CARD11 mutations were detected in nearly one third of patients. CCR4 is important for T-cell migration into the skin. All CCR4 mutations were either nonsense or frameshift and located at the C-terminus. CARD11 is required for T cell receptor (TCR)-mediated activation of NF-κB signaling. About half of the CARD11 mutations were located in the domain previously reported in diffuse large B cell lymphoma (DLBCL). The remaining mutations were located at a highly conserved new hotspot. As was previously suggested in DLBCL, therapies targeting CARD11 signaling could benefit SS patients. PLCG1 is a key modulator of TCR signaling. In addition to the recently reported S345F hotspot mutation, we identified a new hotspot located in the C-terminal of the protein. The mutation frequency of the new hotspot was significantly higher in patients with prior history of MF, suggesting the possibility that PLCG1 may play a role in transformation of MF to SS. Focal deletion of ZEB1 was observed in over half of the patients. ZEB1 is suggested to be critical for early T-cell development. ZEB1 downregulation contributes to resistance to TGF-β1-mediated growth suppression in adult T-cell leukemia/lymphoma derived cell lines. Loss of ZEB1 may play a similar role in SS pathogenesis. IL32 and IL2RG were strongly upregulated in nearly all patients. IL32 protein expression is correlated with the mRNA expression and the density of Sézary cells in patients’ blood. IL32 accelerates the proliferation of CTCL cell lines through mitogen-activated protein kinase and NF-κB-mediated signaling. IL32 could become a target that is specific to SS patients. Surprisingly, the UVB mutation signature was detected in most of the cases, indicating that the malignant clonal population arose from a cell that spent significant time in the superficial layers of the skin and challenging the view that SS originated from the circulating memory T-cell rather than those resident in the skin. Our results showed profound disruption of key T-cell signaling in SS patients and suggested potential targets for novel therapies. Citation Format: Linghua Wang, Xiao Ni, Kyle R. Covington, Liu Xi, David A. Wheeler, Madeleine Duvic. Molecular pathogenesis of an advanced cutaneous T-cell lymphoma. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 124.

P068 A history of mycosis fungoides: from Alibert to mogamulizumab

H03 (P068) A history of mycosis fungoides: from Alibert to mogamulizumab

When mycosis fungoides seems not to be within the spectrum of clinical and histopathological differential diagnoses

Mycosis fungoides: Current trends in diagnosis and management

Mycosis fungoides and Sézary syndrome: clinical presentation, diagnosis, staging, and therapeutic management

A case report of refractory advanced-stage mycosis fungoides: successful treatment and improved patient quality of life with mogamulizumab

A Man with Worsening Scaling Plaques and a New Onset Large Draining Ulcerated Tumor

Systemic involvement in mycosis fungoides

Folliculotropic mycosis fungoides associated with atopic dermatitis

Clinical characteristics, risk factors and long-term outcome of 114 patients with folliculotropic mycosis fungoides

Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk‐stratification, and management

Progression of mycosis fungoides occurs through divergence of tumor immunophenotype by differential expression of HLA-DR

Mycosis fungoides in pediatric patients: Clinical features, diagnostic challenges, and advances in therapeutic management

Primary cutaneous, epidermotropic mycosis fungoides-like presentation: critical appraisal and description of two novel cases, broadening the spectrum of ALK+ T-cell lymphoma

Mechanism of action of chlormethine gel in mycosis fungoides

Multi-Omic Data Integration Suggests Putative Microbial Drivers of Aetiopathogenesis in Mycosis Fungoides

Mimicry unveiled: The challenging diagnosis of pigmented purpura-like mycosis fungoides initially misdiagnosed as pigmented purpura

Abstract 124: Molecular Pathogenesis of an Advanced Cutaneous T-cell Lymphoma

Transcriptomic changes during stage progression of mycosis fungoides

Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers

PA13 A hair’s breadth from misdiagnosis